Financial Performance - BioCardia reported a net loss of approximately $2.7 million for Q1 2025, compared to a net loss of approximately $2.3 million for Q1 2024, reflecting a 17.4% increase in losses year-over-year[9] - BioCardia's cash and cash equivalents decreased to $949,000 as of March 31, 2025, down from $2.37 million at the end of 2024[16] - Total liabilities increased to $3.23 million as of March 31, 2025, compared to $2.32 million at the end of 2024, indicating a rise in financial obligations[16] Research and Development - Research and development expenses were approximately $1.5 million for Q1 2025, up from approximately $1.2 million in Q1 2024, primarily due to activities related to the CardiAMP HF Trial[9] - The CardiAMP autologous cell therapy demonstrated an average 107-second increase in exercise tolerance and an 82% average reduction in angina episodes at the six-month follow-up[2] - The two-year results from the CardiAMP HF Trial showed statistically significant improvements in survival and reduced cardiovascular events, with a p-value of 0.02 in the subset of patients with elevated NTproBNP[3] - The CardiALLO cell therapy trial completed its low dose cohort of 20 million cells with no adverse events reported, and the study is set to progress to 39 participants in the U.S.[4] Regulatory and Intellectual Property - The Helix biotherapeutic delivery system had no procedure-related deaths or complications in the recent CardiAMP HF Trial, supporting the ongoing FDA approval submission[5] - The company holds a robust intellectual property portfolio with over 60 patents and applications worldwide, including a recently granted patent in Japan[6][7] - Upcoming milestones include regulatory submissions for the CardiAMP Cell Therapy System and the Helix delivery system, anticipated within the current quarter[8]
BioCardia(BCDA) - 2025 Q1 - Quarterly Results